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Background: Uptake of prevention of mother-to-child HIV transmission (PMTCT) programs remains challenging in
sub-Saharan Africa because of multiple barriers operating at the individual or health facility levels. Less is known
regarding the influence of program-level and contextual determinants. In this study, we explored the multilevel
factors associated with coverage in single-dose nevirapine PMTCT programs.
Methods: We analyzed aggregate routine data collected within the framework of the ViramuneW Donation
Programme (VDP) from 269 sites in 20 PMTCT programs and 15 sub-Saharan countries from 2002 to 2005. Site
performance was measured using a nevirapine coverage ratio (NCR), defined as the reported number of women
receiving nevirapine divided by the number of women who should have received nevirapine (observed HIV
prevalence x number of women in antenatal care [ANC]). Data on program-level determinants were drawn from
the initial application forms, and country-level determinants from the Demographic and Health Surveys (DHS) and
the World Bank (World Development Indicators). Multilevel linear mixed models were used to identify independent
factors associated with NCR at the site-, program- and country-level.
Results: Of 283,410 pregnant women attending ANC in the included sites, 174,312 women (61.5%) underwent HIV
testing after receiving pre-test counselling, of whom 26,700 tested HIV positive (15.3%), and 22,591 were dispensed
NVP (84.6%). Site performance was highly heterogeneous between and within programs. Mean NCR by site was
43.8% (interquartile range: 19.1-63.9). Multilevel analysis identified higher HIV prevalence (Beta coefficient: 25.1, 95%
confidence interval [CI] 18.7 to 31.6), higher proportion of persons with knowledge of PMTCT (8.3; CI 0.5 to 16.0),
higher health expenditure as a proportion of Gross Domestic Product (3.9 per %; CI 2.0 to 5.8) and lower percentage of
rural population (−0.7 per %; CI −1.0 to −0.5) as significant country-level predictors of higher NCR at the p<0.05 level. A
medium ANC monthly activity (30-100/month) was the only site-level predictor found (−7.6; CI −15.1 to −0.1).
Conclusions: Heterogeneity of nevirapine coverage between sites and programs was high. Multilevel analysis
identified several significant contextual determinants, which may warrant additional research to further define
important multi-level and potentially modifiable determinants of performance of PMTCT programs.
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Since the HIV epidemic began, children have borne a
significant part of the burden of morbidity and mortality.
Mother-to-child transmission (MTCT) of HIV, occurring
principally during labour, was responsible for approxi-
mately 390,000 new infections in 2010 [1]. Of great con-
cern is the situation in sub-Saharan African countries,
where the largest share of new HIV infections among
children worldwide occurs and where women account
for 59% of the adults living with HIV infection. Over the
past two decades, improved interventions in industrial-
ized nations have reduced MTCT rates to less than 2%
[2,3]. In resource-poor countries, applicable measures to
reduce transmission include safer delivery practices, in-
fant feeding counselling and support, and use of anti-
retroviral (ARV) treatment or MTCT prophylaxis [4]. In
this field, the prophylactic administration of single–dose
nevirapine (NVP) to mothers and newborns has been a
crucial step in the prevention of MTCT (PMTCT), due
to its convenient administration, low price and high effi-
cacy [5,6]. Single-dose NVP has therefore gained an im-
portant role during the 2000’s and been widely available
in low-income countries, largely through donation-based
public and private PMTCT programs. Since that early
period, the availability of a number of ARV interventions
has grown steadily worldwide thanks to ambitious inter-
national initiatives [7,8]. Current guidelines have evolved
to now recommend the use of more efficient and com-
plex multidrug antiretroviral treatment (ART) regimens
for PMTCT [9,10].
Despite considerable progress made thus far, improving
prevention program effectiveness in the field still remains
a complex challenge, as suggested by discrepancies often
observed between anticipated and actual uptake of ser-
vices [4,11]. In low- and middle-income countries, an
estimated 35% of pregnant women were tested for HIV
in 2010, and 48% of those living with HIV received the
most effective regimens (excluding single-dose NVP)
for preventing MTCT [1]. Studies have described a
range of potential barriers to program performance, at
both the individual level where socioeconomic and
psychological factors could play a role [12], and the
health facility level where the uninterrupted supply of
HIV tests and antiretroviral drugs, the infrastructure
quality or the presence of properly trained staff and
counselling capabilities are important determinants of
effectiveness [13-15]. Yet less is known about the con-
textual factors that could operate at a broader scale and
determine to various extents the performance of pre-
ventive or therapeutic programs. In this context, multi-
level modeling techniques have proven useful to assess
the independent roles and interactions between factors
nested at different levels [16], including individual-,
site-, program- or country-level characteristics thatcould partly explain or modulate the effectiveness of
PMTCT programs scale-up.
A better knowledge of these multidimensional con-
straints could help improve final coverage and guarantee
program success. In addition, there is still great interest
in documenting lessons learned from the implementa-
tion of single-dose NVP programs, given probable simi-
larities between such challenges and those that programs
based on more complex ARV interventions might en-
counter. Consequently, the objective of this study was
to assess the site-, program- and country-level charac-
teristics associated with NVP coverage levels achieved




We used aggregate monitoring and evaluation data col-
lected within the framework of the ViramuneW Donation
Programme (VDP). ViramuneW (nevirapine) has been of-
fered to developing countries since 2000 by Boehringer
Ingelheim. Axios International has been responsible for
the management of NVP distribution and monitoring of
participating PMTCT programs. All sub-Saharan African
countries were eligible for participation in VDP. The
nevirapine donation was available to governments directly,
as well as Non Governmental Organisations (NGOs),
international organisations and public and private health
care providers with government approval.
Among VDP participating programs (45 programs in-
cluding 1,776 sites in 23 countries at the time of the
study), we selected those with data available by site or
single-site programs. During the study period (January
2002 to December 2005), a total of 269 sites were in-
cluded, participating in 20 PMTCT programs in 15 sub-
Saharan countries (Benin, DR Congo, Côte d'Ivoire, Gabon,
Ghana, Kenya, Lesotho, Malawi, Nigeria, Rwanda, South
Africa, Tanzania, Togo, Uganda and Zambia). No statis-
tically significant differences between selected and not-
selected VDP programs were identified with respect to
their main characteristics, including institution status,
mean number of sites, mean ANC per program per month
and mean HIV prevalence (data not shown; p>0.05).
Primary outcome
To assess the overall performance of PMTCT sites, a
coverage indicator was calculated. The NVP coverage
ratio (NCR) was defined as the [observed number of
women receiving NVP] divided by [the expected num-
ber of women who should have received NVP]. This
denominator was calculated as the number of women
attending antenatal care (ANC) visits multiplied by the
observed HIV seroprevalence at each site (number of
HIV-positive women/ number of HIV-tested women).
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Following acceptance to VDP, participating institutions
were required to submit a progress report every six to
12 months with the following data for each site: number
of women registered in antenatal care, number of HIV-
tested and HIV-positive women and number of women
receiving NVP tablets. These data did not permit assess-
ment of the number of newborn NVP doses provided.
The mean NCR over the period of follow-up was calcu-
lated for each site from all available progress reports.
Predictors assessed at the site level included the site-
observed HIV prevalence, the site activity (number of
women receiving ANC), and the type of health facility
(primary or secondary/tertiary hospital level).
Program- and country-level data
Inclusion in VDP required programs to submit a descrip-
tive application form and receive approval by a body of
independent experts. We collected the following data in
application forms: type of responsible institution or organ-
isation (public/private) and number of sites included.
Variables collected at the national level were drawn
from the Demographic and Health Surveys (DHS) [17]
and the World Bank’s World Development Indicators
[18], including: HIV prevalence (among 15–49 year-old
persons), AIDS knowledge (percentage having heard of
AIDS, comprehensive knowledge [4 components] and
knowledge of PMTCT), HIV-related stigma (percentage
of respondents with accepting attitudes towards persons
living with AIDS), HIV testing coverage (percentage of
respondents tested for HIV and having received their
results in the last 12 months), GDP per capita (Gross
Domestic Product, $), total healthcare expenditure (%
of GDP), and rural population (% of total population).
We gathered publicly available indicators at the na-
tional level, because the mean number of sites per sub-
national area defined by DHS data was too low for
meaningful statistical analysis (<5 sites per region).
Statistical methods
Descriptive statistics were computed for the characteristics
of the PMTCT programs and are provided as medians
(Interquartile Range [IQR]) for quantitative variables and
as percentages for qualitative variables. NCR dispersion
across sites was assessed by using univariate boxplots.
Non-parametric Spearman correlation rank tests (rs) were
used to assess univariate correlation of NCR with inter-
mediate process indicators (women tested rate, women
treated rate).
Multilevel linear mixed models were used in univariate
and multivariate analyses to identify factors associated
with NCR, accounting for the hierarchical clustering of
sites (level 1) nested in programs (level 2) within countries
(level 3). The following multivariate modeling strategy wasapplied: predictors associated with NCR at the p<0.2 level
in univariate analysis were entered sequentially, starting
from level 1 to level 2 and 3, using a backward stepwise
method at each level. Beta coefficients are given for each
predictor variable, indicating the adjusted difference in
NCR (0–100) between categories for qualitative variables
or per 1-point difference in predictor value for continuous
variables. Rural population proportion and total healthcare
expenditure group-level predictors were modeled continu-
ously after checking for linearity of the regression coeffi-
cients. The initial variance partition between levels was
explored in an empty (null) model without any predictor.
The proportional change in the variance (PCV) was
then computed in the final model for each level: PCV
was defined as the proportion of variance “explained”
from the variance initially estimated in the null-model.
A two-tailed P-value of less than 0.05 was considered to
be significant. All statistical analyses were performed
using Stata, version 11.0 (StataCorp, College Station,
TX, USA).
Role of funding source
Boehringer Ingelheim had no role in study design, data
collection, data analysis, data interpretation, or manu-
script development. The corresponding author had full
access to all data in the study and had final responsibility
for the decision to submit for publication. All data




Table 1 summarizes the main characteristics of the
20 programs and 269 sites included in the study.
Overall, cumulative follow-up was 2374 months (median:
9.1 months/program) and 283,410 pregnant women
attended ANC services in the sites included over the
study period. Fifty-five percent of the programs were
conducted by private institutions or NGOs. The median
number of sites included per program was 3.5 and the
majority were primary health facilities (69%).
Global nevirapine coverage results
Of the 283,410 pregnant women attending antenatal
care, 174,312 women (61.5%) were offered, accepted and
underwent HIV testing after receiving pre-test counsel-
ling, of whom 26,700 (15.3%) tested HIV positive. After
post-counselling, 22,591 women (84.6%) were eventually
dispensed NVP. Using these figures, the global NCR was
52.0%. Considering the performance rates per site, the
mean testing coverage was 61.5% (IQR 42.2 - 83.8), the
mean treatment rate was 70.2% (IQR 50.0 - 98.6) while
the mean NCR per site was 43.8% (IQR 19.1 – 63.9).
NCR differed greatly across sites ranging from 0.0 to




Median follow-up length in months (IQR*) 9 (5 – 16)
Institution responsible
Public Programs 9 (45%)
Sites 113 (42%)
Private/NGO** Programs 11 (55%)
Sites 156 (58%)
Number of sites per program
Median (IQR) 3.5 (1–14)
Mean (min-max) 13.5 (1–80)
African region
Eastern Africa Programs 4
Sites 89
Expected HIV prevalence 6.7
Western Africa Programs 6
Sites 62
Expected HIV prevalence 4.4
Central Africa Programs 6
Sites 51
Expected HIV prevalence 2.7
Southern Africa Programs 4
Sites 67
Expected HIV prevalence 16.0
Sites (n=269)
Mean monthly ANC*** activity, # of women (IQR) 116 (58 – 175)
Type of health facility
Primary care clinic 185 (69%)
General or University Hospital 84 (31%)
* IQR: Interquartile range.
** Non governmental organization.
*** Antenatal Care.
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Figure 1. NCR was positively correlated with the women
tested rate (rs=0.65, p=0.01) and women treated rate
(rs=0.62, p=0.01).
Nevirapine coverage determinants
Results from univariate multilevel analysis of PMTCT
performance by site-, program- and country-level pre-
dictors are shown in Table 2. No significant difference
was observed between primary care clinics and general
or university hospitals, after accounting for the hierarch-
ical structure of the data through the use of multilevel
mixed models. The ANC activity level was correlated
with NCR, though in a U-shape, showing lower resultsin sites with a medium number of women in care (30–
100 women/month). Performance results for programs
directed by public institutions did not differ significantly
from those directed by private ones. Size of program
(number of sites) was not significantly associated with
better results in testing, treatment or NVP coverage
rates, though larger programs had a higher NCR point
estimate. Significantly higher performance ratios were
achieved by sites from southern Africa (67.9%) and by
sites in countries with the highest HIV prevalence, test-
ing coverage and percentage of population with know-
ledge about PMTCT.
Multivariate analysis using linear mixed models (Table 3)
identified at the site-level a moderate ANC activity
(30-100/month) as a negative predictor of NVP cover-
age (NCR −7.6 when compared to the reference lowest
activity category; p=0.05). At the country-level, HIV
prevalence (NCR +25.1 for the highest prevalence cat-
egory; p<0.0001), the proportion of persons with know-
ledge of PMTCT (NCR +8.3 for the highest knowledge
category; p<0.0001) and health expenditure as propor-
tion of total GDP (NCR +3.9 per % of increasing GDP;
p<0.0001) were significantly and positively associated
with higher NVP coverage, whereas the percentage of
rural population was negatively associated with NCR
(NCR −0.74 per % of increasing rural population;
p<0.0001). There was no significant association found
in multivariate models between NCR and the propor-
tion of persons with comprehensive knowledge about
AIDS, testing coverage or the African region.
Of the initial total variance of NCR measured in the
null-model including no site- or program/country-level
predictors, 58.5% was found at the site-level and 41.5%
at the program/country level (2.7% [program-level] +
38.8% [country-level]). To determine the proportion of
variance explained by the predictors retained in the
final model, we computed the PCV for each level: PCV
was 99.9% for the program/country level whereas only
0.22% of the site-level variance was explained by the
final model.
Discussion
In this study, we analysed aggregate data from 283,410
pregnant women attending 269 PMTCT sites. We iden-
tified several factors operating at the country-level that
significantly influenced nevirapine coverage in women,
including PMTCT knowledge, HIV prevalence, rural
population proportion and proportion of GDP dedi-
cated to healthcare expenditure. These factors were
independent of site-level factors, such as the site activity
or the type of health facility, and program-level factors,
such as the status of the institution or the program burden
measured as the number of sites included. To our know-





































Figure 1 Site performance dispersion by PMTCT program: Nevirapine Coverage Ratios (NCR). Boxplots are displayed for programs including at
least two sites (n=14) as follows: the median is represented by a horizontal line within each box, which represents the interquartile range (IQR)
comprising data between the 25th and 75th percentiles. Whiskers extend to the 1.5*IQR beyond each box and circles represent outliers.
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the formalized framework of multilevel modeling. The
contextual predictors identified explained almost 100%
of the initial variance at the program/country level. Our
data also showed a huge heterogeneity of performance
between sites within the same programs.
Among 269 PMTCT sites, we found a nevirapine cover-
age ratio of only 44%. Our result is only somewhat more
optimistic than a study by Temmerman et al. reporting a
NVP administration rate of 20%, using a similar whole-
ANC-population-based calculation process [19]. The take-
up testing rate by site was 61.5%, while other studies
reported testing rates ranging from 21% to 95% [20-24].
This variability is echoed in our data, since women tested
percentages differed across programs from 7% to 97%.
Test acceptability after pre-test counselling is variable
but overall high ranging from 72% to 97%, as indicated
in several previous reports [19,25-27]. In regards to NVP
provision to HIV positive pregnant women by site, our
finding of 70.2% is consistent with other previous reports
indicating rates from 56% to 94% [19,21,23,24,26-31].
Specific PMTCT and general comprehensive know-
ledge about AIDS were significantly associated with higher
nevirapine coverage, whereas general awareness about
AIDS – as measured by the proportion of persons who
had heard of AIDS – and accepting attitudes or stigma
were not significantly linked to NCR. This is consistent
with previous reports showing knowledge as an import-
ant factor of success in antiretroviral adherence [32] or
breastfeeding practices [33]. Above all, this result is
encouraging to programs aiming to increase knowledge
about PMTCT and AIDS, which is a potentially modifi-
able contextual determinant. The absence of a signifi-
cant result for stigma in our study requires cautious
interpretation since methods for quantifying stigma areneither straightforward nor consensual. Beyond the dif-
ficult medical prognosis, knowledge of HIV positive
status is of great social consequence, and stigma and
violence are still actual threats for African women
[34-36]. Other factors must be taken into consideration
for improving HIV test acceptance, such as educational
background, familial environment and most importantly
male-spousal involvement. Disclosure of HIV status re-
mains problematic [37] and a woman's perception of her
husband’s approval of testing plays a crucial role in this
context [38].
The national prevalence of HIV remained significant
after accounting for knowledge about AIDS and healthcare
expenditure. In this context, the interpretation of this
indicator might be of interest because it likely encap-
sulates several other contextual features (e.g. testing
coverage, which lost its statistical significance in multi-
variate analysis) or other factors not assessed in our
analysis. Thus, we may interpret national HIV preva-
lence as an awareness and readiness marker indicative
of both population and health services.
Rural population as a percent of total population was
negatively associated with NCR. This result is consistent
with the loss to follow-up of pregnant women [21], as
maternal NVP coverage has been reported to be associ-
ated with the number of ANC visits [39]. The quality
of follow-up remains a challenge for rural and remote
facilities [40]. Interestingly, positive results can been
achieved by providing antiretroviral prophylaxis for mother
and infant early in pregnancy [12,41] or by offering labor
ward-based services for PMTCT [42]. Beyond single-dose
nevirapine regimens, rural primary health facilities likely
face other difficulties as well, such as the capacity to
determine the CD4 cell count required to implement
more efficacious antiretroviral regimens [43].
Table 2 Univariate multilevel analysis of PMTCT performance by site-, program- and contextual-level predictors:
testing, treating and nevirapine coverage ratio (NCR)






Type of health facility
Primary care clinic 185 61.6 0.79 73.8 0.47 46.8 0.53
General or University Hospital 84 61.2 62.4 37.4
Activity (antenatal care)
< 30 / month 90 61.6 0.01 73.7 0.06 45.5 0.05
30 - 100 / month 84 56.7 63.5 35.8
>100 / month 95 65.6 72.8 49.4
Program characteristics
Type of institution responsible
Public 113 62.5 0.81 66.4 0.28 42.8 0.47
Private/NGO 156 60.8 72.9 44.6
Number of sites
<Median (1–3) 16 56.4 0.27 61.9 0.92 35.3 0.38
>Median (4–80) 253 61.8 70.7 44.4
Country-level characteristics
African region
South 67 81.2 0.23 82.2 0.05 67.9 0.03
West 62 52.0 67.9 35.7
Centre 51 65.6 53.8 33.8
East 89 50.9 72.2 37.1
Prevalence of HIV (% of 15-49y)
<Median (1.2-5.4) 110 57.8 0.32 61.1 0.002 34.4 0.01
>Median (6.4-23.4) 159 64.0 76.5 50.4
% Tested for HIV
<Median (2.8-6.3) 95 54.7 0.22 66.4 0.14 35.7 0.05
>Median (7.1-19.6) 170 65.8 72.9 48.9
% Have heard of AIDS
<Median (91.8-96.9) 101 59.1 0.79 70.6 0.98 42.8 0.92
>Median (98.8-99.9) 165 63.6 70.8 45.2
% Accepting (stigma)
<Median (5.1-29.3) 131 62.8 0.66 70.8 0.31 45.0 0.26
>Median (30.2-48.5) 134 60.9 70.4 43.3
% With knowledge about PMTCT
<Median (2.7-33.1) 121 53.6 0.09 67.2 0.14 34.8 0.01
>Median (33.3-66.2) 144 68.8 73.5 52.0
% With comprehensive knowledge about AIDS
<Median (18.7-30.5) 89 53.4 0.17 66.7 0.54 35.0 0.12
>Median (36.5-55.3) 163 63.6 70.7 45.2
Rural population (% of total population)
<Median (17.1-65.0) 122 67.3 0.26 76.2 0.44 53.4 0.18
>Median (68.4-87.6) 147 57.3 66.8 37.2
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Table 2 Univariate multilevel analysis of PMTCT performance by site-, program- and contextual-level predictors:
testing, treating and nevirapine coverage ratio (NCR) (Continued)
Healthcare expenditure (% of GDP*)
<Median (3.0-6.7) 171 50.9 <10-4 70.5 0.92 36.4 0.10
>Median (7.0-10.0) 98 80.0 69.7 56.9
GDP per capita ($)
<Median (144.6-615.8) 141 57.1 0.58 66.7 0.80 36.9 0.75
>Median (1295.3-13338.8)) 128 66.4 74.1 51.5
*Gross Domestic Product.
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was an independent and positive predictor of nevirapine
coverage, probably suggesting an overall positive impact
of increased investment in the organization and infra-
structure of health services. This finding may confirm
the importance of overall health system strength to
ensure effective PMTCT services in the field, where
performance is notably linked to sites’ infrastructure
and testing capacities [13,14] as illustrated in our study by
the strong association found between this indicator and
the testing rate by site.
At the site-level, the highest and lowest nevirapine
coverage results could be observed within the same
program, emphasizing challenges to the on-the-ground
feasibility of PMTCT programs. Beyond infrastructure
and testing capacities, lack of sufficient and well trained
staff have been suggested to explain some of the discrep-
ancies observed between sites. Integration of voluntary
counselling and testing (VCT) services in pre-existing
ANC settings represents an undeniable additional work-
load for in-place health workers. At the same time and
for economic reasons, human resources have not alwaysTable 3 Multivariate multilevel analysis of PMTCT performanc
nevirapine coverage ratio (NCR)
Site characteristics
Activity (antenatal care)
< 30 / month
30 - 100 / month
>100 / month
Country-level characteristics
Prevalence of HIV (% of population ages 15–49)
<Median (1.2-5.4)
>Median (6.4-23.4)
% With knowledge about PMTCT
<Median (2.7-33.1)
>Median (33.3-66.2)
Health expenditure (% of GDP*)
Rural population (% of total population)
*Gross Domestic Product.risen adequately [19,20,25]. Efficient counselling activity
requires trained staff fulfilling specific capabilities [25,44].
Test acceptability and women’s satisfaction are moreover
strongly related to the capacity of PMTCT services to pro-
vide good quality counselling and follow-up care to preg-
nant women [45]. In our study, a moderate ANC activity
(30–100 pregnant women attending ANC services per
month) was associated with lower nevirapine coverage
ratios. This finding could illustrate the negative effect of
increased workload in medium size facilities, where more
difficulties may have been encountered to adjust to the
increased resource requirements for PMTCT.
We consider the generalizability of our findings in the
context of global PMTCT programs. We included VDP
programs with data available by site or one-site pro-
grams, which raises the question of the representative-
ness of the sites included, both in regard to the whole
VDP program and to other existing PMTCT programs.
We did not identify any significant difference between
included and not-included VDP programs regarding their
main characteristics, which suggests limited selection bias
within the VDP program itself. As for the other PMTCTe by site-, program- and contextual-level predictors:
β Coefficient p-value (95% CI)
0 (ref ) -
−7.6 0.05 (−15.1 ; -0.06)
−2.3 0.59 (−10.7 ; 6.1)
0 (ref ) -
25.1 <10-4 (18.7 ; 31.6)
0 (ref ) -
8.3 0.04 (0.53 ; 16.0)
3.9 <10-4 (2.0 ; 5.8)
−0.74 <10-4 (−1.0 ; -0.46)
Audureau et al. BMC Public Health 2013, 13:286 Page 8 of 10
http://www.biomedcentral.com/1471-2458/13/286programs, our program panel cannot be considered as
fully representative of all programs, implemented either
within the same countries or elsewhere in sub-Saharan
Africa and/or based on different antiretroviral drugs and
regimen designs. However, our analysis was conducted
on a range of sites and programs, including primary or
secondary/tertiary health facilities with various ANC
activities within programs from several different sub-
Saharan African regions, thereby supporting the exter-
nal validity of our results. Secondly, a possible selection
bias cannot be excluded in regards to the pregnant
women included in this study, since only women actu-
ally attending ANC services were considered. Finally,
our findings stem from an early era in large scale im-
plementation of PMTCT services, when antiretroviral
interventions were based on much simpler regimens than
the multi-drug regimens currently recommended [9,10].
However, we believe that most of the factors identified in
the present work as determinants of NVP coverage are
likely to apply to current antiretroviral interventions as
well. Barriers such as a limited access to services in remote
rural areas or the influential role of population knowledge
about PMTCT still have resonance today. Thus there is
still great interest in documenting such obstacles, espe-
cially because they were encountered with an intervention
as simple as single-dose NVP and may also extrapolate to
the much more complex interventions of today. More
generally, our results also highlight the potential interest
in promoting the use of multilevel analyses when assessing
factors affecting program scale-up, be it in the framework
of PMTCT or other public health domains. Multilevel ap-
proaches are useful for researchers and can bring relevant
information to policy makers by weighing the relative
impact of site-, program- or contextual-level predictors
of successful implementation of health programs.
Our study has several limitations that should be noted.
In particular, we were not able to control whether a
pregnant woman actually took the NVP dose she was
dispensed in PMTCT services. Specifically, we lacked the
ability to directly measure the drug compounds contained
in cord blood samples, which is an accurate and useful
means to counter the limited quality of reported medical
data when assessing program coverage [39]. NCR tends to
overestimate overall PMTCT coverage, since it does not
account for women without access to PMTCT services.
We believe NCR can still yield at a glance a direct indica-
tor of the process quality of a PMTCT program or site,
encompassing VCTand final NVP administration. Further,
we were not able to use DHS sub-national data for this
study, given low sample size by area unit (mean number
of sites by region <5). Yet, even considering large entities
such as countries, a high between-country heterogeneity
was observed with respect to contextual factors and NVP
coverage, indicating that country-level indicators couldstill represent relevant variables to assess the ‘average’ con-
textual environment of the sites within countries. Finally,
our results should be interpreted cautiously since we
lacked complementary data to describe health facilities
(e.g. staff training), as illustrated by the low percentage
of variance explained at the site-level in multilevel ana-
lysis, or programs (e.g. availability of adherence support
services). It is also likely that some relationships identi-
fied between NCR and country-level factors, such as
the proportion of rural population or healthcare ex-
penditure, may partially but not entirely be explained
by uncontrolled site-level factors (i.e. rural/urban facil-
ity, quality of infrastructure) that were not available in
our dataset.
Conclusion
In conclusion, we observed a wide range of coverage out-
comes among PMTCT sites and programs. To explain
these discrepancies, we identified several country-level fac-
tors, including knowledge about PMTCT and AIDS or the
proportion of GDP allocated to healthcare, adjusting for a
variety of site- and program-level characteristics. Our find-
ings illustrate the potential role of surrounding contextual
and global health system features, in addition to local
characteristics of sites. While qualitative and quantitative
research is still needed at the site level, the overall under-
standing of factors associated with program performance
would benefit from further research that attempts to iden-
tify more distant but important and potentially modifiable
determinants of success.
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